Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 3 (2006), Issue 12 (December)

  1. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials.
    Nat Clin Pract Oncol, 3(12): 658-67. [Abstract] [Full-text]
  2. A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats.
    J Steroid Biochem Mol Biol, 103(1): 76-83. [Abstract] [Full-text]
  3. Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer.
    Int J Cancer, 120(3): 539-42. [Abstract] [Full-text]
  4. Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
    J Urol, 177(1): 359-64. [Abstract] [Full-text]
  5. Quality of life for men receiving a second treatment for prostate cancer.
    J Urol, 177(1): 273-8; discussion 278-9. [Abstract] [Full-text]
  6. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
    J Urol, 177(1): 128-30. [Abstract] [Full-text]
  7. High dose rate brachytherapy as a boost for the treatment of localized prostate cancer.
    J Urol, 177(1): 123-7; discussion 127. [Abstract] [Full-text]
  8. Initial results using a running vesicourethral anastomosis following open radical retropubic prostatectomy.
    J Urol, 177(1): 118-22; discussion 122. [Abstract] [Full-text]
  9. Changing nature of high risk patients undergoing radical prostatectomy.
    J Urol, 177(1): 113-7. [Abstract] [Full-text]
  10. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
    J Urol, 177(1): 107-12; discussion 112. [Abstract] [Full-text]
  11. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
    J Urol, 177(1): 102-6; discussion 106. [Abstract] [Full-text]
  12. Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men.
    J Urol, 177(1): 97-101; discussion 101. [Abstract] [Full-text]
  13. Bone health in men receiving androgen deprivation therapy for prostate cancer.
    J Urol, 177(1): 17-24. [Abstract] [Full-text]
  14. Imaging of prostate cancer.
    Radiol Clin North Am, 45(1): 207-22. [Abstract] [Full-text]
  15. Mitoxantrone-related acute myeloblastic leukaemia in a patient with metastatic hormone-refractory prostate cancer.
    Anticancer Drugs, 18(2): 233-5. [Abstract] [Full-text]
  16. Effects of interactions of EGCG and Cd(2+) on the growth of PC-3 cells and their mechanisms.
    Food Chem Toxicol, 45(2): 244-9. [Abstract] [Full-text]
  17. Survival associated with treatment vs observation of localized prostate cancer in elderly men.
    JAMA, 296(22): 2683-93. [Abstract] [Full-text]
  18. Androgen deprivation in veterans with prostate cancer: implications for skeletal health.
    Ann Pharmacother, 40(12): 2107-14. [Abstract] [Full-text]
  19. D,L-Sulforaphane-induced cell death in human prostate cancer cells is regulated by inhibitor of apoptosis family proteins and Apaf-1.
    Carcinogenesis, 28(1): 151-62. [Abstract] [Full-text]
  20. Reactive oxygen species regulate insulin-induced VEGF and HIF-1alpha expression through the activation of p70S6K1 in human prostate cancer cells.
    Carcinogenesis, 28(1): 28-37. [Abstract] [Full-text]
  21. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Hum Pathol, 38(1): 161-70. [Abstract] [Full-text]
  22. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
    Hum Pathol, 38(1): 72-8. [Abstract] [Full-text]
  23. TSP1 and MMP9 genetic variants in sporadic prostate cancer.
    Cancer Genet Cytogenet, 172(1): 38-44. [Abstract] [Full-text]
  24. Effect of 17beta-estradiol on apoptosis, IGF system components and gelatinases A and B in prostate cancer cells (PC-3).
    Clin Chim Acta, 377(1): 70-8. [Abstract] [Full-text]
  25. Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.
    Clin Chim Acta, 377(1): 103-7. [Abstract] [Full-text]
  26. Statin drugs and risk of advanced prostate cancer.
    J Natl Cancer Inst, 98(24): 1819-25. [Abstract] [Full-text]
  27. Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI.
    AJR Am J Roentgenol, 188(1): 99-104. [Abstract] [Full-text]
  28. Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.
    AJR Am J Roentgenol, 188(1): 91-8. [Abstract] [Full-text]
  29. Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology.
    AJR Am J Roentgenol, 188(1): 84-90. [Abstract] [Full-text]
  30. Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult.
    Cancer Res, 66(24): 11998-2008. [Abstract] [Full-text]
  31. The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer.
    Cancer Res, 66(24): 11983-90. [Abstract] [Full-text]
  32. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
    Cancer Res, 66(24): 11897-906. [Abstract] [Full-text]
  33. Androgens regulate protein kinase Cdelta transcription and modulate its apoptotic function in prostate cancer cells.
    Cancer Res, 66(24): 11792-801. [Abstract] [Full-text]
  34. DNA methylation pathway alterations in an autochthonous murine model of prostate cancer.
    Cancer Res, 66(24): 11659-67. [Abstract] [Full-text]
  35. Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram.
    Radiology, 242(1): 182-8. [Abstract] [Full-text]
  36. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.
    Mol Pharmacol, 71(1): 259-75. [Abstract] [Full-text]
  37. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients.
    Invest New Drugs, 25(2): 139-46. [Abstract] [Full-text]
  38. Occupational risk factors for prostate cancer and benign prostatic hyperplasia: a case-control study in Western Australia.
    Occup Environ Med, 64(1): 60-5. [Abstract] [Full-text]
  39. Image-guided in vivo dosimetry for quality assurance of IMRT treatment for prostate cancer.
    Int J Radiat Oncol Biol Phys, 67(1): 288-95. [Abstract] [Full-text]
  40. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.
    Int J Radiat Oncol Biol Phys, 67(1): 84-90. [Abstract] [Full-text]
  41. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients.
    Int J Radiat Oncol Biol Phys, 67(1): 78-83. [Abstract] [Full-text]
  42. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 67(1): 65-70. [Abstract] [Full-text]
  43. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).
    Int J Radiat Oncol Biol Phys, 67(1): 39-47. [Abstract] [Full-text]
  44. A magnetic resonance imaging study of prostate deformation relative to implanted gold fiducial markers.
    Int J Radiat Oncol Biol Phys, 67(1): 48-56. [Abstract] [Full-text]
  45. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience.
    Int J Radiat Oncol Biol Phys, 67(1): 57-64. [Abstract] [Full-text]
  46. Bypassing the learning curve in permanent seed implants using state-of-the-art technology.
    Int J Radiat Oncol Biol Phys, 67(1): 71-7. [Abstract] [Full-text]
  47. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3.
    Cancer Lett, 247(1): 122-9. [Abstract] [Full-text]
  48. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
    Prostate, 67(2): 203-13. [Abstract] [Full-text]
  49. Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells.
    Prostate, 67(2): 135-45. [Abstract] [Full-text]
  50. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy.
    Prostate, 67(2): 162-71. [Abstract] [Full-text]
  51. Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells.
    Prostate, 67(2): 125-34. [Abstract] [Full-text]
  52. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
    Prostate, 67(2): 172-7. [Abstract] [Full-text]
  53. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
    Prostate, 67(2): 154-61. [Abstract] [Full-text]
  54. A role for neurotensin in bicalutamide resistant prostate cancer cells.
    Prostate, 67(2): 190-202. [Abstract] [Full-text]
  55. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Prostate, 67(2): 178-89. [Abstract] [Full-text]
  56. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
    Prostate, 67(2): 214-25. [Abstract] [Full-text]
  57. Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain.
    Prostate, 67(2): 146-53. [Abstract] [Full-text]
  58. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
    J Clin Oncol, 25(1): 77-84. [Abstract] [Full-text]
  59. Increased risk of breast cancer associated with CHEK2*1100delC.
    J Clin Oncol, 25(1): 57-63. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

Beating Prostate Cancer (Hormonal Therapy & Diet, 1)

Beating Prostate Cancer (Hormonal Therapy & Diet, 1)